SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Autoimmune Archive
We maintain news archives for the most recent 3 years.
2019: Jan Feb Mar Apr May Jun Jul Aug
2019 - 2018 - 2017 - 2016

August 2019 Autoimmune News

Sarcoidosis. Sarcoidosis is an inflammatory disorder of unknown cause that is characterized by granuloma formation in affected organs, most often in the lungs. PubMed, Nat Rev Dis Primers, 2019 Jul 4;5(1):45. (Also see Sarcoidosis)

Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis (AAV): Is There Still a Role for Cyclophosphamide (CYC)? With the emergence of newer agents with more favorable safety profiles, CYC is no longer the cornerstone of management of AAV. PubMed, Rheum Dis Clin North Am, 2019 Aug;45(3):379-398. (Also see Vasculitis and Immunosuppressants)

The associations of TNF-α gene polymorphisms with bone mineral density and risk of osteoporosis: A meta-analysis. The present meta-analysis demonstrated that TNF-α G308A polymorphism may act as a potential candidate biomarker for screening, diagnosis, and treatment of osteoporosis. PubMed, Int J Rheum Dis, 07/04/2019. (Also see Osteoporosis)

Heart failure (HF) risk in systemic lupus erythematosus (SLE) compared to diabetes mellitus (DM) and general medicaid patients. Further investigation into the biologic mechanism of HF among SLE compared to non-SLE and DM patients may shed light on the findings of this study. PubMed, Semin Arthritis Rheum, 06/11/2019. (Also see Symptoms and Complications of Lupus and Symptoms and Complications of Diabetes)

Effect of disease-modifying anti-rheumatic drugs (DMARDs) on bone structure and strength in psoriatic arthritis (PsA) patients. Despite longer disease duration, bDMARD-treated PsA patients benefit from higher bone mass and better bone strength than PsA patients receiving methotrexate or no DMARDs. PubMed, Arthritis Res Ther, 2019 Jul 3;21(1):162. (Also see Psoriasis and Psoriatic Arthritis and Disease-Modifying Anti_Rheumatic Drugs)

Anti-D4GDI antibodies activate platelets in vitro: a possible link with thrombocytopenia in primary antiphospholipid syndrome. We show here that antibodies anti-D4GDI are present in the sera of PAPS patients and can prime platelet activation, explaining, the pro-thrombotic state and the thrombocytopenia of PAPS patients. PubMed, Arthritis Res Ther, 2019 Jul 1;21(1):161. (Also see Antiphospholipid Syndrome)

Incidence and patterns of malignancies in a multi-ethnic cohort of rheumatoid arthritis (RA) patients. There is a trend toward an overall increased malignancy risk in our RA patients compared to the general population. PubMed, Int J Rheum Dis, 07/11/2019. (Also see Symptoms and Complications of Rheumatoid Arthritis)

Association of TNFSF4 rs1234315, rs2205960 polymorphisms and systemic lupus erythematosus (SLE) susceptibility: a meta-analysis. The present study suggested that TNFSF4 rs1234315 and rs2205960 polymorphisms were associated with SLE susceptibility. PubMed, Lupus, 2019 Jul 12:961203319862610. (Also see Causes of Lupus)

Comparison of Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) expression, inflammatory markers and cardiovascular risk in patients with acute coronary syndrome (ACS) with and without rheumatoid arthritis (RA). Our results indicate that exRANKL, inflammatory markers and mortality risk are amplified in ACS patients with RA compared to ACS patients without RA. PubMed, Rheumatol Int, 07/11/2019. (Also see Symptoms and Complications of Rheumatoid Arthritis)

Complement alternative pathway activation associated with pulmonary hypertension in lupus nephritis patients. Activation of the complement alternative pathway may be involved in the pathogenesis of pulmonary hypertension in lupus nephritis. PubMed, Lupus, 2019 Jul 11:961203319860192. (Also see Symptoms and Complications of Lupus and Pulmonary Hypertension)

Go to Autoimmune News: July 2019
 

Many thanks to our recent donors, Network for Good. See ISN News for more donors. Click Here to Donate.

 

TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.

We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, report bad links, or update page content. Disclaimer. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!

DONATE